Showing results (621-630 of 963) with videos related to
Sort By:
Pageof 97
Nature Communications|February 10, 2025
Chromosome-level genomes of two Bracteacoccaceae highlight adaptations to biocrustsHongping Liang, Yan Xu, Sunil Kumar Sahu, et al.European Journal of Gastroenterology & Hepatology|June 6, 2014
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infectionAdrian M Di Bisceglie, Mark Sulkowski, Ed Gane, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 17, 2007
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis BEmmet B Keeffe, Stefan Zeuzem, Raymond S Koff, et al.JHEP Reports : Innovation in Hepatology|September 29, 2023
Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D studyMarianne Martinello, Sanjay Bhagani, David Shaw, et al.Liver International : Official Journal of the International Association for the Study of the Liver|November 1, 2015
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter studyDonald M Jensen, Michael Brunda, Robert Elston, et al.Journal of Crohn'S & Colitis|December 15, 2015
Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative ColitisMisagh Alipour, Deenaz Zaidi, Rosica Valcheva, et al.Plos One|June 17, 2021
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertibGianluigi Giannelli, Armando Santoro, Robin K Kelley, et al.Journal of Hepatology|December 8, 2016
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvirDavid Wyles, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.Clinical and Translational Gastroenterology|July 12, 2019
A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular CarcinomaR K Kelley, E Gane, E Assenat, et al.Science (New York, N.Y.)|January 18, 2014
A promiscuous intermediate underlies the evolution of LEAFY DNA binding specificityCamille Sayou, Marie Monniaux, Max H Nanao, et al.Pageof 97